Increased mortality in patients w/ target hematocrit of 42%. Control BP before initiation of therapy. Chronic renal failure patients w/ uncontrolled HTN; seizures. Underlying hematologic disease; patients w/ history of seizure disorder or underlying hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes or hyper coagulable disorders); porphyria. Fe deficiency; underlying infectious, inflammatory or malignant processes; occult blood loss; folic acid or vit B12
deficiencies; hemolysis; Al intoxication; osteitis fibrosa cystica. May require increased anticoagulation w/ heparin to prevent clotting of the artificial kidney. Pregnancy & lactation.